Stacie Weninger, Ph.D.
Stacie Weninger is the president of F-Prime Biomedical Research Initiative, an affiliate of F‑Prime Capital created to advance research in Alzheimer’s disease and related brain disorders. Prior to FBRI, she was the senior director of science programs for the Fidelity Foundations. Before that, Stacie served as the project manager and senior analyst for the Task Force on Women in Science at Harvard University and was a senior scientist at Cell Press for the journal Neuron.
Stacie currently chairs the Collaboration for Alzheimer’s Prevention; is president of Alzforum; serves as chairman of the board of Directors for Rugen Therapeutics; serves as a member of the board of directors for Aratome, Atalanta, Eikonizo, Neumora, Sironax and Target ALS; and serves as a member of the scientific advisory boards for the Indian Institute of Science’s Centre for Brain Research and the UK Dementia Research Institute. She is also a member of Pfizer’s genetics scientific advisory panel. She previously served as a founding member of the board of directors for Denali Therapeutics, as well as a member of the board of directors for Abelian (acquired by Neumora), Annexon Biosciences, BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix, Syllable Life Sciences (acquired by Neumora) and Q-State Biosciences.
Earlier in her career, Stacie was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the program in neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, she was actively involved in undergraduate teaching, winning six teaching awards.
Stacie holds a Ph.D. in neuroscience from Harvard University and a B.S. in chemistry with highest honors from the University of North Carolina, Chapel Hill.